Clinical Trials /

A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)

NCT04752813

Description:

This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatment framework of RT and concurrent TMZ chemotherapy for subjects with newly diagnosed glioblastoma.

Related Conditions:
  • Glioblastoma
Recruiting Status:

Not yet recruiting

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
  • Official Title: A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)

Clinical Trial IDs

  • ORG STUDY ID: BPM31510IV-11
  • NCT ID: NCT04752813

Conditions

  • Glioblastoma
  • Glioblastoma Multiforme

Interventions

DrugSynonymsArms
BPM31510BPM31510, Vitamin K1, RT and TMZ
Temozolomide (TMZ)BPM31510, Vitamin K1, RT and TMZ

Purpose

This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatment framework of RT and concurrent TMZ chemotherapy for subjects with newly diagnosed glioblastoma.

Detailed Description

      The study will start with a dose-confirmation phase to establish safety of BPM31510 in
      combination with RT and TMZ. This phase will follow a standard 3+3 dose design with the
      starting dose of BPM31510 at 110 mg/kg/week (wk), with 1 potential dose de-escalation to 66
      mg/kg/wk in the event a DLT is experienced at the 110 mg/kg dose. Toxicity at this dose level
      will be graded according to National Cancer Institute Common Terminology Criteria for Adverse
      Events version 5 (CTCAE v5). Subjects will be monitored for DLTs associated with combination
      therapy for 30 days (d) (± 5 d) after the end of RT (DLT assessment period). Subjects will
      continue to be monitored for late radiation-related DLTs during follow up, every 8 wk (± 2
      wk) during the first 12 months (mo), and then every 12 wk (± 2 wk) for a total of 5 years
      (y). Safety oversight will be provided by the independent Data and Safety Monitoring
      Committee (DSMC). The DSMC will review and confirm all DLT data, make recommendations for
      dose modifications, if necessary, and continue to monitor safety throughout the study. The
      efficacy phase of the study will begin after the recommended Phase 2 dose (RP2D) has been
      confirmed.
    

Trial Arms

NameTypeDescriptionInterventions
BPM31510, Vitamin K1, RT and TMZExperimentalSubjects will receive a BPM31510 96hr infusion once weekly for 8 wk. Prophylactic Vitamin K1 at a recommended dose of 10 mg will be given intramuscular (IM) to all subjects prior to the beginning of each week of therapy. After 2 wk of treatment with BPM31510, subjects will start concurrent standard RT and TMZ 75 mg/m2 once daily (qd) × 42 days. Subjects will receive the standard TMZ treatment for additional 6 cycles post BPM31510 treatment.
  • BPM31510
  • Temozolomide (TMZ)

Eligibility Criteria

        Inclusion Criteria:

          1. Subjects with newly diagnosed pathologically verified GB.

          2. No prior RT, chemotherapy, immunotherapy, or targeted agents administered specifically
             for the lesion being treated.

          3. Age ≥18 y.

          4. Life expectancy ≥3 months.

          5. Karnofsky performance score ≥60.

          6. Adequate organ and marrow function as per protocol.

          7. Ability for subject to understand and the willingness to sign a written ICF.

          8. Subjects of childbearing potential must agree to use hormonal or barrier birth control
             with spermicidal gel to avoid pregnancy during the study.

          9. Be at least 14 d out from surgery.

        Exclusion Criteria:

          1. No evidence of residual tumor.

          2. History of clinically significant tumor-related cerebral hemorrhage.

          3. Any serious cardiac history as per protocol.

          4. Uncontrolled or severe coagulopathies or a history of clinically significant bleeding
             within the past 6 months.

          5. Known predisposition for bleeding such as von Willebrand's disease or other such
             condition(s).

          6. Uncontrolled concurrent illness.

          7. Prior malignancy except for non-melanoma skin cancer and carcinoma in situ (of the
             cervix or bladder), unless diagnosed and definitively treated more than 3 y prior to
             first dose of study drug.

          8. Receiving any of the following medications:

               1. Therapeutic doses of any anticoagulant, including low-molecular weight heparin.
                  Concomitant use of warfarin, even at prophylactic doses, is prohibited.

               2. Digoxin, digitoxin, lanatoside C, or any type of digitalis alkaloids.

               3. Antiangiogenic drugs (ie, Avastin) either in the past 2 wk or if anticipated
                  within the next 2 wk of informed consent.

               4. Theophylline

          9. Known allergy to CoQ10.

         10. Known allergy or adverse reaction to oral, subcutaneous, or IV Vitamin K1.

         11. Pregnant or lactating.

         12. Known to be positive for the human immunodeficiency virus (HIV). Note: HIV testing is
             not required for eligibility, but if performed previously and was positive, the
             subject is ineligible.
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Efficacy will be assessed by subject progression free survival
Time Frame:6 months
Safety Issue:
Description:Progression free survival will be determined by measuring the proportion of subjects who have met RANO criteria for complete response, partial response , or stable disease at 6 mo following initiation of BPM31510.

Secondary Outcome Measures

Measure:Efficacy will be assessed by subject Overall survival
Time Frame:5 years
Safety Issue:
Description:Overall survival as determined by measuring from start date of BPM31510 to the date of death or date of last follow-up (for subjects who have not died).
Measure:Safety and tolerability of BPM31510 and Vitamin K1 will be assessed by incidence of dose limiting toxicities (DLTs) and adverse events (AEs).
Time Frame:28 days post treatment
Safety Issue:
Description:A DLT is defined as an event possibly related to BPM31510 and clearly not due to an underlying disease or extraneous causes. An AE is defined as any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Not yet recruiting
Lead Sponsor:Berg, LLC

Last Updated

May 13, 2021